Journal of Traditional Chinese Medicine ›› 2024, Vol. 44 ›› Issue (3): 537-544.DOI: 10.19852/j.cnki.jtcm.20240423.003
Previous Articles Next Articles
LI Ruibai1, CHEN Ke2(), MA Wei3, ZHANG Yayue3, HOU Li3, CHEN Xinyi3()
Received:
2023-01-11
Accepted:
2023-04-27
Online:
2024-06-15
Published:
2024-04-30
Contact:
CHEN Ke,CHEN Xinyi
About author:
CHEN Ke, Department of Hemotology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China. 18810482625@163.comTelephone: +86-10-84017637; +86-10-62835362Supported by:
LI Ruibai, CHEN Ke, MA Wei, ZHANG Yayue, HOU Li, CHEN Xinyi. Hemostatic mechanism of Jianpi Yiqi Shexue decoction (健脾益气摄血方) in treatment of immune thrombocytopenia[J]. Journal of Traditional Chinese Medicine, 2024, 44(3): 537-544.
Group | n | Gender (n) | Age (years) | |
---|---|---|---|---|
Male | Female | |||
Normal control | 10 | 3 | 7 | 29±3 |
Dysfunctional uterine bleeding | 16 | 0 | 16 | 31±11 |
Gastrointestinal tumors with bleeding | 12 | 7 | 5 | 67±15 |
ITP | 17 | 1 | 16 | 44±15 |
Table 1 Gender and age ($\bar{x} \pm s$)
Group | n | Gender (n) | Age (years) | |
---|---|---|---|---|
Male | Female | |||
Normal control | 10 | 3 | 7 | 29±3 |
Dysfunctional uterine bleeding | 16 | 0 | 16 | 31±11 |
Gastrointestinal tumors with bleeding | 12 | 7 | 5 | 67±15 |
ITP | 17 | 1 | 16 | 44±15 |
Group | n | 5-HT (ng/mL) | VIP (pg/mL) | β-EP (pg/mL) |
---|---|---|---|---|
Normal control | 10 | 135.10±87.67 | 165.57±102.35 | 4.12±0.26 |
Dysfunctional uterine bleeding | 16 | 98.57±57.24 | 147.43±100.83 | 4.00±0.40 |
Gastrointestinal tumors with bleeding | 12 | 63.56±39.22a | 37.64±18.45a | 3.40±0.29b |
ITP | 17 | 945.68±615.33b | 23.64±35.99b | 2.66±1.84b |
Table 2 Comparison of blood neurotransmitter indexes ??( $\bar{x} \pm s$)
Group | n | 5-HT (ng/mL) | VIP (pg/mL) | β-EP (pg/mL) |
---|---|---|---|---|
Normal control | 10 | 135.10±87.67 | 165.57±102.35 | 4.12±0.26 |
Dysfunctional uterine bleeding | 16 | 98.57±57.24 | 147.43±100.83 | 4.00±0.40 |
Gastrointestinal tumors with bleeding | 12 | 63.56±39.22a | 37.64±18.45a | 3.40±0.29b |
ITP | 17 | 945.68±615.33b | 23.64±35.99b | 2.66±1.84b |
Group | n | Gender (n) | Age (years) | |
---|---|---|---|---|
Male | Female | |||
Treatment | 104 | 28 | 76 | 35±17 |
Combination | 103 | 28 | 75 | 33±17 |
Control | 65 | 20 | 45 | 32±17 |
Table 3 Comparison of gender and age ($\bar{x} \pm s$)
Group | n | Gender (n) | Age (years) | |
---|---|---|---|---|
Male | Female | |||
Treatment | 104 | 28 | 76 | 35±17 |
Combination | 103 | 28 | 75 | 33±17 |
Control | 65 | 20 | 45 | 32±17 |
Time point | FAS | PPS | |||||
---|---|---|---|---|---|---|---|
Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | ||
Before treatment | 2.5±1.4 | 2.5±1.4 | 2.6±1.5 | 2.4±1.3 | 2.5±1.4 | 2.6±1.5 | |
After treatment | 2.3±1.7 | 1.7±1.4a | 1.8±1.5b | 2.2±1.7 | 1.7±1.4a | 1.8±1.5b |
Table 4 Peripheral blood PLT reduction grade scores before and after treatment (×109/L, $\bar{x} \pm s$)
Time point | FAS | PPS | |||||
---|---|---|---|---|---|---|---|
Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | ||
Before treatment | 2.5±1.4 | 2.5±1.4 | 2.6±1.5 | 2.4±1.3 | 2.5±1.4 | 2.6±1.5 | |
After treatment | 2.3±1.7 | 1.7±1.4a | 1.8±1.5b | 2.2±1.7 | 1.7±1.4a | 1.8±1.5b |
Time point | FAS | PPS | |||||||
---|---|---|---|---|---|---|---|---|---|
Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | ||||
Before treatment | 1.6±0.7 | 1.5±0.5 | 1.5±0.7 | 1.6±0.7 | 1.5±0.5 | 1.5±0.7 | |||
7 d after treatment | 1.4±0.5a | 1.2±0.4a | 1.4±0.6 | 1.3±0.5a | 1.2±0.4a | 1.4±0.6 | |||
14 d after treatment | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | |||
After treatment | 1.2±0.6a | 1.1±0.3a | 1.2±0.5a | 1.2±0.6a | 1.1±0.3a | 1.2±0.5a |
Table 5 Comparison of bleeding symptom scores at different visit points ($\bar{x} \pm s$)
Time point | FAS | PPS | |||||||
---|---|---|---|---|---|---|---|---|---|
Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | ||||
Before treatment | 1.6±0.7 | 1.5±0.5 | 1.5±0.7 | 1.6±0.7 | 1.5±0.5 | 1.5±0.7 | |||
7 d after treatment | 1.4±0.5a | 1.2±0.4a | 1.4±0.6 | 1.3±0.5a | 1.2±0.4a | 1.4±0.6 | |||
14 d after treatment | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | 1.2±0.4a | |||
After treatment | 1.2±0.6a | 1.1±0.3a | 1.2±0.5a | 1.2±0.6a | 1.1±0.3a | 1.2±0.5a |
Item | Time point | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | |
---|---|---|---|---|---|
5-HT (ng/mL) | Before treatment | 400±388 | 352±299 | 469±523 | |
After treatment | 475±553 | 349±273 | 609±754a | ||
β-EP (pg/mL) | Before treatment | 6±87 | 7±7 | 8±8 | |
After treatment | 10±9a | 16±39a | 10±10 | ||
VIP (pg/mL) | Before treatment | 14±24 | 13±24 | 17±30 | |
After treatment | 11±19 | 11±18 | 6±7b |
Table 6 Neurotransmitter level changes before and after treatment ($\bar{x} \pm s$)
Item | Time point | Treatment group (n = 104) | Combination group (n = 103) | Control group (n = 65) | |
---|---|---|---|---|---|
5-HT (ng/mL) | Before treatment | 400±388 | 352±299 | 469±523 | |
After treatment | 475±553 | 349±273 | 609±754a | ||
β-EP (pg/mL) | Before treatment | 6±87 | 7±7 | 8±8 | |
After treatment | 10±9a | 16±39a | 10±10 | ||
VIP (pg/mL) | Before treatment | 14±24 | 13±24 | 17±30 | |
After treatment | 11±19 | 11±18 | 6±7b |
1. | Hemostasis and Thrombosis Group, Hematology Branch of Chinese Medical Association. Chinese expert consensus on the diagnosis and treatment of adult primary immune thrombocytopenia. Zhong Hua Xue Ye Xue Za Zhi 2016; 37: 89-93. |
2. | Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115: 168-86. |
3. |
Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American society of hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-207.
DOI URL |
4. | Wang J, Zhang Y, Zhang L, et al. Clinical curative effect observation on treatment of immune thrombocytopenia treated with Jianpi Yiqi Shexue granules. Zhong Hua Zhong Yi Yao Za Zhi 2018; 33: 5700-4. |
5. | Zhang ZN, Shen D. Hematological diagnosis and efficacy standards. 3rd ed. Beijing: Science Press, 2007: 172-3. |
6. | Xie X, Gou WL. Obstetrics and gynecology. 8th ed. Beijing: Health Press, 2013: 180-5. |
7. | National Health and Family Planning Commission of the People's Republic of China. Standardized diagnosis and treatment guidelines for gastric cancer (trial). Zhong Guo Yi Xue Qian Yan Za Zhi (Dian Zi Ban) 2015; 18: 961-73. |
8. | National Health and Family Planning Commission Medical Administration Bureau; Chinese Medical Association Oncology Branch. Standards for diagnosis and treatment of colorectal cancer in China (2015 edition). Zhong Hua Wei Chang Wai Ke Za Zhi 2015; 18: 961-73. |
9. | Zheng XY. Guidelines for clinical research of new Chinese medicine. Beijing: China Medical Science and Technology Press, 2002: 167-8. |
10. | Chen ZL, Zhou YH. General situation of clinical research on treatment of immune thrombocytopenia with Traditional Chinese Medicine. Zhejiang Zhong Yi Za Zhi 2012; 47: 304-5. |
11. | Li YH, Bai YS. Overview of research on immune mechanism of Traditional Chinese Medicine intervention in primary immune thrombocytopenia. Shi Yong Zhong Yi Nei Ke Za Zhi 2015; 29: 166-8. |
12. | Wang MJ, Xu YG, Ding XQ, et al. Cellular immune function in patients with immune thrombocytopenia. Zhong Hua Lin Chuang Yi Shi Za Zhi 2018; 12: 65-9. |
13. | Chen K, Zhang YY, Zhao N, Ma W, Chen XY. Clinical study on the treatment of immune thrombocytopenia from the spleen based on changes in blood neurotransmitters. Beijing Zhong Yi Yao 2017; 36: 780-4. |
14. | Li HN, Ma YL, Zhang W, et al. Based on the theory of brain-gut axis to explore the mechanism of abdominal massage intervention in central nervous system diseases. Liaoning Zhong Yi Za Zhi 2019; 46: 2321-4. |
15. | Guo C, He P. Brain-gut axis and its research progress. Shi Jie Zui Xin Yi Xue Xin Xi Wen Zhai 2017; 17: 89-91. |
16. | Huang GZ, Zhang YD, He GB. The role of brain-gut axis in functional gastrointestinal disease and its research progress. Yi Xue Zong Shu 2013; 19: 447-5. |
17. | Sun B, Chen T, Wang T, Hu C, Zhu JC. Research progress on the interaction between intestinal flora and brain-gut axis. Zhong Guo Wei Sheng Tai Xue Za Zhi 2016; 28: 1206-11. |
18. | CHen YQ, Zhang C, Dong W, Yang XF. Molecular mechanism of neurotransmitter release. Zhong Guo Xi Bao Sheng Wu Xue Xue Bao 2019; 41: 33-41. |
19. | Guo XY, Yang XM, Ye T, Ji B, Feng J, Feng JL. Hydrogen sulfide: a new neuromodulator and protective agent of the central nervous system. Zhong Guo Nao Ke Ji Bing Yu Kang Fu Za Zhi 2016; 6: 60-4. |
20. | ZHou HY, Jiang HW, Wang MJ. Research progress of serotonin and its receptors. Shandong Yi Yao 2014; 54: 90-3. |
21. | Huang LY, Zhang EY, Gao B, Wu XJ, Wang ZT. Research progress on platelet signal transduction and related antiplatelet drugs. Zhong Guo Xin Yao Yu Lin Chuang Yao Li 2014; 25: 378-83. |
22. |
Przyklenk K, Frelinger AL 3rd, Linden MD, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010; 8: 331-40.
DOI PMID |
23. |
Moerland M, Kemme M, Dijkmans A, et al. Modulation of vasoactivity and platelet aggregation by selective 5-HT receptor antagonism in humans. J Cardiovasc Pharmacol 2011; 58: 575-80.
DOI PMID |
24. | Wei W, Sui BD, Liu JW, Han L, Zhang B. The relationship between serotonin and the immune system and its role in immune-related disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012; 28: 999-1001. |
25. | Wang S. Research progress in the clinical application of β-endorphin. Zhong Guo Zhong He Lin Chuang 2000; 16: 255-6. |
26. | He H, Xu Y, Zheng L, et al. Study on the effect of Jianpi Yiqi Shexue Fang on serum SIgA and β-EP in ITP model mice. Zhong Yi Yao Xin Xi 2015; 3: 47-9. |
27. | Huang C, Han LM. Electroacupuncture and immunity. Shandong Yi Yao 2012; 52: 91-2, 100. |
28. | Jia YM, Wang SR. The relationship between β-endorphin and the "spleen" of Traditional Chinese Medicine. Zhejiang Zhong Yi Yao Da Xue Xue Bao 2010; 34: 795-6. |
29. | Wu MY, Hu TM. Research progress of vasoactive intestinal peptide and digestive system diseases. Shi Jie Hua Ren Xiao Hua Za Zhi 2012; 20: 1453-7. |
30. | Cheng XW, Zheng QH, Li XL, Lin Z. Research progress on the intrinsic relationship between vasoactive intestinal peptides and certain gastrointestinal motility disorders. Zhong Guo Quan Ke Yi Xue 2012; 15: 237-41. |
31. | Chen XY, Chen YF. Research progress on the immunomodulatory effects of vasoactive intestinal peptides. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2012; 28: 1107-9. |
32. | Wang C, Li GH. Progress in the study of vasoactive intestinal peptides regulating lymphocyte differentiation. Mian Yi Xue Za Zhi 2010; 26: 275-7. |
33. |
Cryan JF, O'Mahony SM. The microbiome-gut-brain axis: from bowel to behavior. Neurogastroenterol Motil 2011; 23: 187-92.
DOI URL |
34. | Gasbarrini A, Franceschi F, Tartaglione R, et al. Regression of autoimmune thrombocytopenia after eradication of H. pylori. Lancet 1998; 352: 878. |
35. | Sun LH, Meng YH, Hu J, Fan XH, Wang XL. The clinical significance of eradication of Helicobacter pylori in the treatment of idiopathic thrombocytopenic purpura. Xue Shuang Yu Zhi Xue Xue 2010; 16: 213-5. |
36. | Gao SH. Observation on the efficacy of eradication of Helicobacter pylori in the treatment of idiopathic thrombocytopenic purpura. Tianjin Yi Yao 2011; 39: 958-9. |
37. | Jin RR, Xi YM, Chao R, Chen C. Meta analysis of Helicobacter pylori eradication in the treatment of idiopathic thrombocytopenic purpura. Di San Jun Yi Da Xue Xue Bao 2011; 33: 1880-2. |
[1] | FENG Min, JIA Ziming, WAN Ming, FAN Bolin, TANG Xiaoqiao, CHENG Wenhua, SUN Fanzhong. Effectiveness of Fuling (Poria) and its extracts against spleen deficiency in rats via tonifying spleen [J]. Journal of Traditional Chinese Medicine, 2023, 43(3): 501-506. |
[2] | YU Zeyue, HAO Liyu, LI Zongyuan, SUN Jianhui, CHEN Hongying, HUO Hairu, LI Xiaoqin, SHAN Zhongchao, LI Hongmei. Correlation between slow transit constipation and spleen Qi deficiency, and gut microbiota: a pilot study [J]. Journal of Traditional Chinese Medicine, 2022, 42(3): 353-363. |
[3] | Ai Nogami-Hara, Kaori Kubota, Kotaro Takasaki, Takuya Watanabe, Nobuaki Egahira, Hikari Iba, Risako Fujikawa, Shutaro Katsurabayashi, Funda Bolukbasi Hatip, Izzettin Hatip-Al-Khatib, Katsunori Iwasaki. Extract of Yokukansan improves anxiety-like behavior and increases serum brain-derived neurotrophic factor in rats with cerebral ischemia combined with amyloid-β42 peptide [J]. Journal of Traditional Chinese Medicine, 2019, 39(01): 50-58. |
[4] | Liang Qiankun, Mao Lanfang, Du Xiaojuan, Li Yunxia, Yan Yuan, Liang Jingjing, Liu Junhong, Wang Longde, Li Hongfang. Pingwei capsules improve gastrointestinal motility in rats with func-tional dyspepsia [J]. Journal of Traditional Chinese Medicine, 2018, 38(01): 43-53. |
[5] | Liu Yi, Feng Hui, Mo Yali, Gao Jingfang, Mao Hongjing, Song Mingfen, Wang Shengdong, Yin Yan, Liu Wenjuan. Effect of soothing-liver and nourishing-heart acupuncture on early selective serotonin reuptake inhibitor treatment onset for depressive disorder and related indicators of neuroimmunology:a randomized controlled clinical trial [J]. Journal of Traditional Chinese Medicine, 2015, 35(05): 507-513. |
[6] | Xiaofang Wu, Meikui Zhang, Huai Huang. Effect of Qilongtoutong granule on calcitonin gene-related peptide,beta-endorphin, serotonin, dopamine, and noradrenalin in migraine model rats and mice [J]. Journal of Traditional Chinese Medicine, 2014, 34(02): 188-193. |
[7] | Changqing Guo, Naigang Liu, Xiaohong Li, Hongmei Sun, Bo Hu, Jing Lu, Yan Guo, Chuxi Liang, Hong Xu, Haixia Wu. Effect of acupotomy on nitric oxide synthase and beta-endorphin in third lumbar vertebrae transverse process syndrome model rats [J]. Journal of Traditional Chinese Medicine, 2014, 34(02): 194-198. |
[8] | Yubo Li, Yuxiu Sun, Xueling Ma, Xiaoxing Xue, Wenting Zhang, Zhiqian Wu, Yulin Ouyang, Jianxin Chen, Weiming Wang, Shuzhen Guo, Wei Wang. Effects of Sini San used alone and in combination with fluoxetine on central and peripheral 5-HT levels in a rat model of depression [J]. Journal of Traditional Chinese Medicine, 2013, 33(05): 674-681. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
Sponsored by China Association of Chinese Medicine
& China Academy of Chinese Medical Sciences
16 Nanxiaojie, Dongzhimen Nei, Beijing, China. 100700 Email: jtcmen@126.com
Copyright 2020 Journal of Traditional Chinese Medicine. All rights reserved.